NCT03691714 2023-12-08
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Unknown
University of Cincinnati
National Cancer Institute, Naples
University of California, San Diego
ISU Abxis Co., Ltd.
Azienda Ospedaliero-Universitaria Careggi
Institute of Oncology Ljubljana
Theagenio Cancer Hospital
Medical University Innsbruck